General
Preferred name
AVASIMIBE
Synonyms
PD-148515 ()
CI-1011 ()
Avasimibe (CI-1011) ()
Avasimiba ()
Avasimibe ()
P&D ID
PD010835
CAS
166518-60-1
Tags
available
drug candidate
Drug indication
Peripheral vascular disease
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Avasimibe (CI-1011; PD-148515) is an orally active acyl coenzyme A-cholesterol acyltransferase (ACAT; also called SOAT)) inhibitor with IC50s of 24 and 9.2 ¦ÌM for ACAT1 and ACAT2, respectively[1]. Avasimibe can be used for the research of prostate cancer[2].
PRICE 43
DESCRIPTION Avasimibe (PD-148515) is an orally bioavailable inhibitor of acyl-Coenzyme A: cholesterol acyltransferase (ACAT, IC50: 3.3 ??M) that prevents cholesterol deposition in the arterial wall. It also inhibits human P450 isoenzymes CYP2C9/1A2/2C19 (IC50: 2.9/13.9/26.5 ??M).
DESCRIPTION Potent and selective JAK3 inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Avasimibe inhibits Lipoprotein(a) accumulation in the culture media of primary monkey hepatocyte in a dose-dependent manner with 11.9% -31.3% inhibition, the change is mainly associated with decreased ApoA. (BOC Sciences Bioactive Compounds)
DESCRIPTION Avasimibe is an acyl coenzyme A-cholesterol acyltransferase (ACAT; also called SOAT)) inhibitor. Avasimibe can be used for the research of prostate cancer. (Enamine Bioactive Compounds)
DESCRIPTION Avasimibe (PD-148515) is an orally bioavailable inhibitor of acyl-Coenzyme A: cholesterol acyltransferase (ACAT, IC50: 3.3 μM) that prevents cholesterol deposition in the arterial wall. It also inhibits human P450 isoenzymes CYP2C9/1A2/2C19 (IC50: 2.9/13.9/26.5 μM). (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
1
Compound Sets
16
AdooQ Bioactive Compound Library
A10102
BOC Sciences Bioactive Compounds
avasimibe-cas-166518-60-1-item-84-60517
Cayman Chemical Bioactives
18129
ChEMBL Drugs
CHEMBL101309
Drug Repurposing Hub
DrugBank
DB06442
DrugMAP
DMFG4OM
DrugMatrix
Enamine Bioactive Compounds
EBC-11282
Mcule NIBR MoA Box Subset
MCULE-2481071538
MedChem Express Bioactive Compound Library
HY-13215
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
Avasimibe(CI-1011)
TargetMol Bioactive Compound Library
T2753
Tocris Bioactive Compound Library
6505
External IDs
30
Properties
(calculated by RDKit )
Molecular Weight
501.29
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
10
Ring Count
2
Aromatic Ring Count
2
cLogP
7.29
TPSA
72.47
Fraction CSP3
0.55
Chiral centers
0.0
Largest ring
6.0
QED
0.37
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
ACAT
Acyltransferase
CYP1A2
CYP2C19
CYP2C9
CES1
Acyltransferase,P450 (e.g. CYP17)
Primary Target
Acyl-CoA:Cholesterol Acyltransferase
MOA
Inhibitor
ACAT inhibitor
Member status
member
Pathway
Metabolism
Metabolic Enzyme/Protease
Solubility
Soluble in DMSO (Slightly), Ethanol (Slightly), Methanol (Slightly)
Source data